A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients

Trial Profile

A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors CinnaGen
  • Most Recent Events

    • 13 Feb 2018 Planned End Date changed from 22 Nov 2018 to 1 Feb 2020.
    • 13 Feb 2018 Planned primary completion date changed from 22 Feb 2018 to 30 Nov 2019.
    • 29 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top